USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
12 Jul 2022 | 02:45 PM GMT

DTx in Mental Health: Building Clinical & Economic Evidence

Anchored by:

Marie Atallah
Head of therapy
FLOURISH HEALTH

Participants:

Marie Atallah Head of therapyFlourish Health
Marie Atallah
Head of therapyFlourish Health
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Christopher Hall Commercial Director, APACMarula Health
Christopher Hall
Commercial Director, APACMarula Health
Helen Hey Director Business StrategyMerakoi
Helen Hey
Director Business StrategyMerakoi
Kyloon Chuah Co-Founder, Chief Product & Tech OfficerVeriteos
Kyloon Chuah
Co-Founder, Chief Product & Tech OfficerVeriteos
Maxime Champain Search & Evaluation lead, External InnovationBiogen
Maxime Champain
Search & Evaluation lead, External InnovationBiogen
Rani Cohen Co-Founder and Executive ChairmanGray Matters Health
Rani Cohen
Co-Founder and Executive ChairmanGray Matters Health
Ravi Janapureddy Co-founder & CEOResony
Ravi Janapureddy
Co-founder & CEOResony
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC

About this Meeting

Within digital therapeutics (DTx), mental health is an area showing major potential, particularly given that drug compliance tends to be a considerable problem and pharmacological treatments are usually not enough to get the desired outcomes. However, building a strong evidence base is tricky and questions remain about how to trial a digital therapeutic (DTx) in mental health realistically and effectively.  

At this meeting, we will hold a peer-to-peer discussion on how companies approach building a compelling evidence base. More specifically, we will discuss: 

  • When are randomized controlled trials (RCT) needed? : While there may be a presumption that you have to conduct at least one RCT, is this always the case? We will look at how companies should assess their commercialization strategy and the need for RCTs.  
  • Work with real world data: There is often a gap between a controlled trial and how the innovation manifests in reality in a patient's life - something that is particularly relevant within mental health given the complexity of conditions and treatment. How can DTx show evidence of products working in the real world?  
  • Beyond clinical data: As potential partners and payers often look for other proof points - such as medical cost savings, engagement levels, and activation levels - how can DTx harness data?